MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 17,033 shares, a decline of 24.2% from the February 12th total of 22,470 shares. Based on an average daily trading volume, of 112,233 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s stock are sold short. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 112,233 shares, the short-interest ratio is presently 0.2 days.

MDxHealth Stock Down 1.5%

Shares of NASDAQ:MDXH traded down $0.05 during midday trading on Friday, hitting $3.20. The stock had a trading volume of 48,075 shares, compared to its average volume of 109,411. The company has a market cap of $158.40 million, a P/E ratio of -4.78 and a beta of 1.61. MDxHealth has a 12 month low of $1.36 and a 12 month high of $5.33. The business’s 50-day simple moving average is $3.52 and its 200-day simple moving average is $3.78.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Thursday, February 26th. The company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $29.55 million for the quarter, compared to analyst estimates of $26.05 million. As a group, equities analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Analyst Ratings Changes

MDXH has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $7.00 target price on shares of MDxHealth in a report on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Investors Weigh In On MDxHealth

Hedge funds have recently bought and sold shares of the company. Intesa Sanpaolo Wealth Management bought a new position in MDxHealth during the fourth quarter worth about $36,000. GSA Capital Partners LLP bought a new stake in MDxHealth in the third quarter valued at approximately $48,000. Lido Advisors LLC acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $48,000. Squarepoint Ops LLC acquired a new stake in shares of MDxHealth in the fourth quarter valued at approximately $51,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.